CMPX
HealthcareCompass Therapeutics, Inc. · Biotechnology · $290M
What is Compass Therapeutics, Inc.?
Compass Therapeutics is a clinical-stage biopharmaceutical company focused on developing antibody-based treatments for cancer. Headquartered in Boston, Massachusetts, the company is building a pipeline of investigational oncology therapies targeting key tumor biology pathways.
Compass Therapeutics develops antibody-based therapeutics aimed at treating cancer by targeting mechanisms that drive tumor growth and immune evasion. Its pipeline includes bispecific antibodies and monoclonal antibodies designed to disrupt angiogenesis, tumor vascularization, and immune checkpoint pathways. As a clinical-stage company, it does not yet generate product revenue — funding comes from capital markets while it advances candidates through clinical trials toward potential regulatory approval.
Compass Therapeutics was founded in 2021 and is headquartered in Boston, Massachusetts.
- CTX-009: bispecific antibody targeting angiogenesis and tumor vascularization pathways
- CTX-471: CD137 agonist monoclonal antibody for immune activation in cancer
- CTX-8371: bispecific inhibitor targeting PD-1 and PD-L1 immune checkpoints
- Oncology-focused antibody platform for multiple human disease indications
Is CMPX a Good Stock to Buy?
UQS Score rates CMPX as Poor overall, reflecting the early-stage nature of its business and the significant uncertainties that come with a pre-revenue clinical pipeline.
The one area where CMPX stands out relative to its profile is Risk, which earns a Good label — suggesting the company's balance sheet and financial structure carry a more manageable near-term risk profile than many peers at this stage.
Quality, Moat, Growth, and Valuation all present challenges: the company lacks commercial revenue, has no established competitive moat, and the Valuation pillar registers as Elevated — meaning the current market price may not reflect the underlying development risk.
See the full five-pillar breakdown and detailed financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does CMPX pay dividends?
No — Compass Therapeutics, Inc. does not currently pay a dividend.
CMPX does not pay a dividend, which is typical for clinical-stage biopharmaceutical companies. All available capital is directed toward advancing the oncology pipeline through clinical trials. Income-focused investors should be aware that no cash distributions are expected until the company reaches commercial-stage operations, if at all.
When does CMPX report earnings?
Compass Therapeutics reports financial results on a quarterly cadence, consistent with US-listed public companies.
As a pre-revenue clinical-stage company, quarterly reports focus primarily on cash runway, pipeline progress, and research expenditure rather than traditional revenue or profit metrics. Investors typically watch for clinical trial updates and financing activity alongside financial statements.
For the most recent quarter's results and pipeline updates, visit Compass Therapeutics' investor relations page directly.
CMPX Price History
+24.8% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Compass Therapeutics, Inc.?
Based on Compass Therapeutics, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
CMPX Long-term Outlook
The fundamental outlook for CMPX is shaped by its early-stage pipeline and the binary nature of clinical trial outcomes. The Growth pillar is rated Weak, reflecting the absence of commercial revenue and the long timeline to potential product approval. The Risk pillar earns a Good label, which provides some reassurance about near-term financial stability, but the Elevated Valuation suggests the market may already be pricing in optimistic scenarios that have yet to materialize clinically.
Growth drivers
- Advancement of CTX-009 and CTX-471 through clinical milestones
- Potential partnership or licensing deals that validate the antibody platform
- Broader industry tailwinds in oncology immunotherapy development
Key risks
- Clinical trial failure or delays across any pipeline candidate
- Elevated valuation relative to pre-revenue stage increases downside risk
- Ongoing capital requirements and potential dilution from future fundraising
CMPX vs Peers
Compass Therapeutics operates in a competitive clinical-stage oncology space alongside several other development-focused biotechnology companies.
MeiraGTx focuses on gene therapy rather than antibody-based approaches, targeting inherited retinal and neurological conditions alongside oncology.
CytomX develops Probody therapeutics — conditionally activated antibodies designed to improve tumor selectivity and reduce off-target toxicity.
Design Therapeutics pursues a small-molecule platform targeting repeat expansion diseases, differentiating it from CMPX's antibody-centric oncology focus.
Frequently Asked Questions
What does Compass Therapeutics do?
Compass Therapeutics is a clinical-stage oncology company developing antibody-based treatments for cancer. Its pipeline includes bispecific antibodies and monoclonal antibodies targeting pathways that drive tumor growth, vascularization, and immune evasion. The company has not yet commercialized any products.
Does CMPX pay dividends?
No, CMPX does not pay a dividend. Clinical-stage biopharmaceutical companies typically reinvest all capital into research and development. Investors seeking income should be aware that no dividend is expected at this stage of the company's development.
When does CMPX report earnings?
Compass Therapeutics reports on a quarterly cadence, as is standard for US-listed public companies. For exact reporting dates and the most recent financial results, check the investor relations section of the company's official website.
Is CMPX a good stock to buy?
UQS Score rates CMPX as Poor overall. The rating reflects weak Quality, Moat, and Growth pillar scores alongside an Elevated Valuation. The Risk pillar is the relative bright spot. Investors should weigh these factors carefully against their own risk tolerance before making any decision.
Is CMPX overvalued?
The UQS Valuation pillar for CMPX is rated Elevated, suggesting the current market price may not fully account for the risks of a pre-revenue clinical pipeline. This does not predict price direction, but it does indicate that the valuation warrants scrutiny relative to the company's development stage.
How does CMPX compare to its competitors?
CMPX competes in the clinical-stage oncology space alongside companies like CytomX Therapeutics and MeiraGTx. Each pursues different therapeutic modalities — CMPX is antibody-focused, while peers use gene therapy or conditionally activated platforms. The full UQS comparative analysis is available to Pro members.
What is CMPX's market cap bracket?
CMPX is classified as a small-cap company. This places it in a segment of the market that typically carries higher volatility and liquidity risk compared to large- or mega-cap peers, which is common for clinical-stage biopharmaceutical companies.
Who founded Compass Therapeutics?
Compass Therapeutics was founded in 2021. For detailed information about the founding team and leadership history, the company's official website and SEC filings provide publicly available background on its executive and scientific founders.
Is CMPX a long-term quality investment?
As a long-term quality indicator, the UQS Score rates CMPX as Poor. The Weak scores across Quality, Moat, and Growth pillars reflect the absence of established revenue, competitive advantages, and a proven commercial model — all factors that matter for long-term investment quality assessments.
What is the main competitive advantage of Compass Therapeutics?
Compass Therapeutics is building a differentiated antibody platform targeting multiple oncology pathways, including angiogenesis and immune checkpoint mechanisms. However, the UQS Moat pillar is rated Weak, indicating that a durable competitive advantage has not yet been established at this stage of development.
What sector does CMPX belong to?
CMPX operates in the Healthcare sector, specifically within clinical-stage biopharmaceuticals. It focuses exclusively on oncology, developing antibody-based therapeutics for cancer treatment. Investors can explore other [Healthcare sector stocks](/sector/healthcare) rated by UQS Score for broader context.
Is CMPX a growth stock or value stock?
Based on its UQS pillar profile, CMPX does not fit neatly into either category. The Growth pillar is rated Weak due to the absence of commercial revenue, while the Valuation pillar is Elevated — meaning it carries a growth-stock-style premium without the demonstrated growth to support it.
Unlock Full CMPX Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete five-pillar score breakdown for CMPX
- ✓Access detailed financial metrics and trend data
- ✓Compare CMPX against clinical-stage oncology peers
- ✓Screen small-cap biotech stocks by Quality and Risk labels
- ✓Get the full analyst-style view available to Pro members
Pro Analysis
CMPX — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 10, 2026 | 12.8 | 0.0 | 9.0 | 0.5 | 69.5 | 0.0 | +0.1 |
| May 9, 2026 | 12.7 | 0.0 | 9.0 | 0.0 | 69.5 | 0.0 | -0.4 |
| Apr 2, 2026 | 13.1 | 0.0 | 9.0 | 0.6 | 71.5 | 0.0 | — |
CMPX — Pillar Breakdown
Quality
— 0.0/100 (25%)Compass Therapeutics, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Free cash flow relative to market value.
Growth
— 0.5/100 (20%)Compass Therapeutics, Inc. faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 69.5/100 (15%)Compass Therapeutics, Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Compass Therapeutics, Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 9/100 (25%)Compass Therapeutics, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for CMPX.
Score Composition
Financial Data
More Stock Analysis
How is the CMPX UQS Score Calculated?
The UQS (Unified Quality Score) for Compass Therapeutics, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Compass Therapeutics, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Compass Therapeutics, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.